Predicting side effects from immune therapy in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop and validate a risk prediction model for serious non-hematological side effects in patients undergoing immune checkpoint inhibitor therapy for solid tumors. It will assess various risk factors, including age, gender, and medical history, to determine their impact on the likelihood of developing adverse events. Additionally, the study will track patient-reported quality of life and adverse events over a 12-month period, while also evaluating cytokine levels as potential predictors of toxicity. The findings may help clinicians make more informed treatment decisions in the future.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must be planning to receive ICI-based therapy for a solid tumor malignancy. This therapy must be given according to Food and Drug Administration (FDA) label or National Comprehensive Cancer Network (NCCN) guidelines at Category 1 or 2A and not in the context of a clinical trial
* Participants who have received prior ICI-based therapy must have completed ICI based therapy at least 180 days prior to registration
* Participants must not have discontinued any prior ICI-based therapy (if applicable) because of irAE
* Participants must not have received chemotherapy, biologic, or targeted-therapy within 21 days prior to registration
* Participants must have recovered from side effects of prior therapy to the following standards per treating physician's discretion:

  * =\< Grade 1 for any non-hematologic side effects (excluding neuropathy and alopecia); lab-related parameters of liver and renal function will be considered at the discretion of the treating physician)
  * =\< Grade 2 for neuropathy and/or alopecia
  * Grade 3 or less for any hematologic side effects
* Participants must be planning to begin standard of care ICI-based therapy within 3 calendar days after registration
* Participants must not be planning to receive ICI-based therapy in combination with chemotherapy or any other non-ICI therapy for treatment of their cancer
* Participants must be at least 18 years of age
* Participants must complete their history and physical examination within 28 days prior to registration
* Participants who can complete the S2013 Feasibility Questionnaire in English or Spanish must participate at the scheduled assessments
* Participants must be able to complete Patient-Reported Outcome (PRO) instruments in English, Spanish, or French and must be planning to complete PROs at all scheduled assessments
* Participants must complete the pre-registration (baseline) PRO forms within 14 days prior to registration
* Participants must be willing to participate in PRO data collection

  * Note: Prior to registration, participants must decide on their method (paper or electronic) of completing their follow-up questionnaires. Participants who elect electronic (ePRO) completion must have an iPhone, Android phone, or tablet with cellular or WiFi connectivity in order to download the Patient Cloud mobile applications onto the device (personal device or a site provisioned device for multi-users)
* Participants must be offered the opportunity to participate in the optional specimen banking
* Note: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

  * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Where it's running

• Anchorage Associates in Radiation Medicine
  Anchorage, Alaska, United States Recruiting
• Alaska Breast Care and Surgery LLC
  Anchorage, Alaska, United States Recruiting
• Alaska Oncology and Hematology LLC
  Anchorage, Alaska, United States Recruiting
• Alaska Women's Cancer Care
  Anchorage, Alaska, United States Recruiting
• Katmai Oncology Group
  Anchorage, Alaska, United States Recruiting
• Providence Alaska Medical Center
  Anchorage, Alaska, United States Recruiting

+799 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Krishna S Gunturu — SWOG Cancer Research Network

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if virtual informed consent methods help people decide to join cancer research

  This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT07805083

• AI-powered supportive care chatbot for young adult cancer survivors

  A chatbot driven by artificial intelligence is tested to help young adult cancer survivors manage symptoms and care needs after treatment.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07772596

• Telehealth pharmacist-led opioid education for cancer patients

  This pilot tests a telehealth group education session led by a palliative care pharmacist to help adults with cancer use opioids more safely and effectively.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT07737314

• Mindfulness program to help with symptoms in chronic graft-versus-host disease

  A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07733141

• Non-invasive brain stimulation to help chemotherapy-induced nerve problems in cancer survivors

  This trial tests whether a gentle brain stimulation method (tDCS) can help reduce numbness, tingling, and pain from CIPN in cancer survivors who are not currently in treatment.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07673614

• Couples Coping Together Against Cancer: A Feasibility and Acceptability Look

  This observational study tests whether a brokered program for patients with cancer and their partners is feasible and acceptable, and whether it may reduce distress over time.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07664579

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.